Rate My Professor Glen Reid

Reid's academic interests center on translational cancer research, including the emergence of drug-tolerant persister cells in lung cancer and melanoma, the role of microRNAs in mesothelioma biology, biomarker discovery, and nucleic acid-based cancer therapies. Current projects explore KRAS expression in drug tolerance, untranslated p53 mRNA in drug resistance, and strategies to inhibit adaptive mutability. He received a $195,892 research grant from the Cancer Society of New Zealand to investigate drug-tolerant cells during cancer treatment. Key publications include 'Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma' (The Lancet Oncology, 2017), 'Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence' (Cancer Gene Therapy, 2025), 'MicroRNA mimics based on the miR-15/107 consensus sequence sensitise NSCLC cells to targeted therapy' (International Journal of Molecular Sciences, 2026), 'Asbestos-Related lung Cancer: An underappreciated oncological issue' (2024), and 'Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma' (British Journal of Cancer, 2025). His research has garnered over 12,000 citations, influencing advancements in mesothelioma diagnostics and therapies.